Biohaven Ltd.
BHVNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Biohaven Ltd. focuses on Biotechnology services and products. Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. Valued at $2.37B, BHVN is a mid-cap name in its sector. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Market Cap
$2.37B
Beta
3.17
P/E (TTM)
—
P/E (Fwd)
-8.10
EPS (TTM)
$-4.55
EPS (Fwd)
$-1.94
ROE
-799.5%
ROA
-72.0%
Cash
$267.9M
Total Debt
$297.0M
Free CF
-$256.2M
52W Change
8.4%
Annual Financials
Cash vs Debt
Where BHVN stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, BHVN finished 30.15% above its 150-day moving average ($11.84) and 33.65% above its 200-day moving average ($11.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BHVN overbought or oversold?
At the August 31, 2026 close, BHVN's RSI(14) was 55.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $267.9M in cash, though total debt stands at $297.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$256.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -799.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 3.17 means BHVN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Biohaven Ltd. and its sector.